Company performance
Add to research
Current Price
as of Feb 07, 2025$120.29
P/E Ratio
17.29
Market Cap
$7.27B
Description
Add to research
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Metrics
Add to research
Overview
- HQDublin, DU
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerJAZZ
- Price$120.29+0.18%
Trading Information
- Market cap$7.27B
- Float95.74%
- Average Daily Volume (1m)500,860
- Average Daily Volume (3m)581,686
- EPS$7.45
Company
- Revenue$3.99B
- Rev growth (1yr)8.52%
- Net income$215.05M
- Gross margin74.50%
- EBITDA margin40.33%
- EBITDA$425.44M
- EV$10.62B
- EV/Revenue2.66
- P/E17.29
- P/S1.90
- P/B1.74
- Debt/Equity148.69
Documents
Add to research
SEC Filings
Factset Street Account
Earnings Calls
Wikipedia